PATENT 4301-1064-1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: CZOLLNER et al.

Appl. No.: New Group: Unknown

Filed: August 26, 2003 Examiner: Unknown

For: NEW BENZAZEPINE DERIVATIVES, DRUGS

CONTAINING THESE AND USE OF THE SAME FOR

PRODUCING DRUGS

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Assistant Commissioner for Patents Date: August 26, 2003 P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s). U.S. Filing Date(s)

09/242,339 February 11, 1999

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 25-0120.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

YOUNG & THOMPSON

Philip A. DuBois, #50,696

PD/psf

745 South 23rd Street Arlington, Virginia 22202 (703) 521-2297

(Rev. 04/19/2000)

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)					Attorney Docket No.: 4301-1064-1		Application No.: NEW			
					Applicant: CZOLLNER et al.					
					Filing Date: August 26, 2003			Group Art Unit:		
		U	S. PATEN	1T	DOCUMENTS					
Examiner Initial	Document Number	Date		Name		Clas	s S	Subclass	Filing date (if appropriate	
milia	3,947,445			HENRY et al.						
	5,428,159			SHIEH et al.			-			
· 	5,336,675 6,043,359				SNORRASON CZOLLNER et al.					
	0,043,339	IVICIT.	2000		ZEIVEIV GUAI.					
					NT DOOLMENTO					
			· · · · · · · · · · · · · · · · · · ·	1	NT DOCUMENTS	01		Subclass	Trong	slation
Examiner Initial	Document Number		Date		Country	Ci	ass	Subciass	Yes	No
	0 236 684 0 345 808		Sep. 1987		EUROPE					
			Dec. 1989		EUROPE					
	0 653 427	***	May 1995		EUROPE				_	ļ
	WO 88/08708		Nov. 1988		INTERNATIONAL					
	WO 95/27715		Oct. 1995		INTERNATIONAL			ļ		
	EP 648 771		Apr. 1995		EUROPE					
	WO 96/12692		May 1996 Sep. 1989		INTERNATIONAL NETHERLANDS			 		├
	8800350		Sep. 1969		NETHERLANDS			ļ		
					⊔ hor, Title, Date, Pertiner					L
	P. Remuzon, "Fluo 2898-2909	ronapht	hyridines as	Ant	tibacterial Agents.", J. Me	d. Chen	n., 1	992, Vol.	35, pag	jes
		_					****			
			 	•						
				т.						
EXAMIN	IER:			D	ATE CONSIDERED					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

^{*} Abstract provided for the Examiner's convenience